Exact Mass: 167.0365

Exact Mass Matches: 167.0365

Found 112 metabolites which its exact mass value is equals to given mass value 167.0365, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Thioguanine

2-Amino-1,7-dihydro-6H-purine-6-thione

C5H5N5S (167.0266)


Thioguanine is only found in individuals that have used or taken this drug. It is an antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. [PubChem]Thioguanine competes with hypoxanthine and guanine for the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) and is itself converted to 6-thioguanilyic acid (TGMP), which reaches high intracellular concentrations at therapeutic doses. TGMP interferes with the synthesis of guanine nucleotides by its inhibition of purine biosynthesis by pseudofeedback inhibition of glutamine-5-phosphoribosylpyrophosphate amidotransferase, the first enzyme unique to the de novo pathway of purine ribonucleotide synthesis. TGMP also inhibits the conversion of inosinic acid (IMP) to xanthylic acid (XMP) by competition for the enzyme IMP dehydrogenase. Thioguanine nucleotides are incorporated into both the DNA and the RNA by phosphodiester linkages, and some studies have shown that incorporation of such false bases contributes to the cytotoxicity of thioguanine. Its tumor inhibitory properties may be due to one or more of its effects on feedback inhibition of de novo purine synthesis; inhibition of purine nucleotide interconversions; or incorporation into the DNA and RNA. The overall result of its action is a sequential blockade of the utilization and synthesis of the purine nucleotides. CONFIDENCE standard compound; INTERNAL_ID 640; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1594; ORIGINAL_PRECURSOR_SCAN_NO 1590 CONFIDENCE standard compound; INTERNAL_ID 640; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1575; ORIGINAL_PRECURSOR_SCAN_NO 1574 CONFIDENCE standard compound; INTERNAL_ID 640; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1573; ORIGINAL_PRECURSOR_SCAN_NO 1568 CONFIDENCE standard compound; INTERNAL_ID 640; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1582; ORIGINAL_PRECURSOR_SCAN_NO 1581 CONFIDENCE standard compound; INTERNAL_ID 640; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1583; ORIGINAL_PRECURSOR_SCAN_NO 1581 CONFIDENCE standard compound; INTERNAL_ID 640; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1576; ORIGINAL_PRECURSOR_SCAN_NO 1575 CONFIDENCE standard compound; INTERNAL_ID 640; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 855; ORIGINAL_PRECURSOR_SCAN_NO 852 CONFIDENCE standard compound; INTERNAL_ID 640; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 853; ORIGINAL_PRECURSOR_SCAN_NO 850 CONFIDENCE standard compound; INTERNAL_ID 640; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 852; ORIGINAL_PRECURSOR_SCAN_NO 850 CONFIDENCE standard compound; INTERNAL_ID 640; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 872; ORIGINAL_PRECURSOR_SCAN_NO 869 CONFIDENCE standard compound; INTERNAL_ID 640; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 865; ORIGINAL_PRECURSOR_SCAN_NO 862 CONFIDENCE standard compound; INTERNAL_ID 640; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 863; ORIGINAL_PRECURSOR_SCAN_NO 861 L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01B - Antimetabolites > L01BB - Purine analogues C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2254 - Amidophosphoribosyltransferase Inhibitor D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents 6-Thioguanine (Thioguanine; 2-Amino-6-purinethiol) is an anti-leukemia and immunosuppressant agent, acts as an inhibitor of SARS and MERS coronavirus papain-like proteases (PLpros) and also potently inhibits USP2 activity, with IC50s of 25 μM and 40 μM for Plpros and recombinant human USP2, respectively.

   

Taurocyamine

2-[(diaminomethylidene)amino]ethane-1-sulfonic acid

C3H9N3O3S (167.0365)


Taurocyamine is a guanidino-taurine analogue derived from taurine. It is an intermediate of taurine and hypotaurine metabolism. The concentration of taurocyamine present in the human urine and serum could be as low as 8-78 pmol/ml. (PMID: 6520173) Plasma levels of taurocyamine are significantly increased in patients with chronic renal failure with or without hemodialysis. (PMID: 10516995). Taurocyamine is an endogenous alkaline "shifter". It effectively reduces the extent of brain intracellular lactic acidosis brought about by anoxic insult. A pH alkaline shift may protect the brain against the deleterious effects of lactic acidosis. (PMID: 8241459). Taurocyamine is an inhibitor of taurine transport and a glycine receptor antagonist in the brain (PMID: 12411417). [HMDB] Taurocyamine is a guanidino-taurine analogue derived from taurine. It is an intermediate of taurine and hypotaurine metabolism. The concentration of taurocyamine present in the human urine and serum could be as low as 8-78 pmol/ml. (PMID: 6520173) Plasma levels of taurocyamine are significantly increased in patients with chronic renal failure with or without hemodialysis. (PMID: 10516995). Taurocyamine is an endogenous alkaline "shifter". It effectively reduces the extent of brain intracellular lactic acidosis brought about by anoxic insult. A pH alkaline shift may protect the brain against the deleterious effects of lactic acidosis. (PMID: 8241459). Taurocyamine is an inhibitor of taurine transport and a glycine receptor antagonist in the brain (PMID: 12411417).

   

Phenylacetothiohydroximate

phenylthioacetohydroximic acid

C8H9NOS (167.0405)


   

8-Hydroxyguanine

8-Hydroxyguanine

C5H5N5O2 (167.0443)


   

2-Acetamidoethylphosphonate

2-Acetamidoethylphosphonate

C4H10NO4P (167.0347)


   

8-Hydroxyguanine

1H-Purine-6,8-dione, 2-amino-7,9-dihydro-1H-purine-6,8-dione

C5H5N5O2 (167.0443)


Formation of 8-hydroxyguanine (8-OHG), a mutagenic base which is a marker for OH-mediated DNA damage, requires peroxidase and halides and occurs in the presence of transition metal chelators (DTPA +/- desferrioxamine), and is inhibited by catalase, superoxide dismutase (SOD), and scavengers of hypohalous acids. (PMID 10820020). 8-Hydroxyguanine is an oxidative stress marker for diagnosis of Alzheimers disease (AD). (PMID 15977989). Formation of 8-hydroxyguanine (8-OHG), a mutagenic base which is a marker for OH-mediated DNA damage, requires peroxidase and halides and occurs in the presence of transition metal chelators (DTPA +/- desferrioxamine), and is inhibited by catalase, superoxide dismutase (SOD), and scavengers of hypohalous acids. (PMID 10820020)

   

2,8-Dihydroxyadenine

6-Amino-1H-purine-2,8(3H,7H)-dione

C5H5N5O2 (167.0443)


2,8-Dihydroxyadenine is a Purine metabolite usually not detectable in biofluids of normal individuals; this insoluble metabolite (at physiological urinary pH) cause urinary tract calculi and arthritis, and is identified in Adenine phosphoribosyltransferase deficiency (APRT, OMIM 102600). (PMID 16613999) In APRT, 2,8-dihydroxyadenine (DHA) accumulates in crystals within the tubular lumens (a feature of many kidney stone diseases) creating crystal-induced injury in human kidney epithelial cells. (PMID 16374038) Urinary DHA crystals are easily recognized under a microscope, and effective treatment can be offered and therefore the prognosis depends upon the renal function at diagnosis; treatment consists of adequate fluid intake, a low-purine diet and administration of allopurinol. (PMID 15764278) [HMDB] 2,8-Dihydroxyadenine is a Purine metabolite usually not detectable in biofluids of normal individuals; this insoluble metabolite (at physiological urinary pH) cause urinary tract calculi and arthritis, and is identified in Adenine phosphoribosyltransferase deficiency (APRT, OMIM 102600). (PMID 16613999) In APRT, 2,8-dihydroxyadenine (DHA) accumulates in crystals within the tubular lumens (a feature of many kidney stone diseases) creating crystal-induced injury in human kidney epithelial cells. (PMID 16374038) Urinary DHA crystals are easily recognized under a microscope, and effective treatment can be offered and therefore the prognosis depends upon the renal function at diagnosis; treatment consists of adequate fluid intake, a low-purine diet and administration of allopurinol. (PMID 15764278).

   

4-Methylthiobenzamide-S-oxide

(4-methylphenyl)(sulfinylidene)methanamine

C8H9NOS (167.0405)


   

Carboxyethylphosphoramide

3-[(diaminophosphoryl)amino]propanoic acid

C3H10N3O3P (167.046)


   

xanthine amine

1-amino-2,3,6,7-tetrahydro-1H-purine-2,6-dione

C5H5N5O2 (167.0443)


   

N-dimethylethanolamine phosphate

dimethyl[2-(phosphonatooxy)ethyl]azaniumyl

C4H10NO4P (167.0347)


N-dimethylethanolamine phosphate is soluble (in water) and a moderately acidic compound (based on its pKa). N-dimethylethanolamine phosphate can be found in a number of food items such as green zucchini, cucumber, breadfruit, and peach, which makes N-dimethylethanolamine phosphate a potential biomarker for the consumption of these food products.

   

Butanoic acid, 2-amino-4-(hydroxyphosphinyl)-

Butanoic acid, 2-amino-4-(hydroxyphosphinyl)-

C4H10NO4P (167.0347)


   

Hydroxyakalone

Hydroxyakalone

C5H5N5O2 (167.0443)


   

7-Hydroxyguanine

7-Hydroxyguanine

C5H5N5O2 (167.0443)


   

delta-Aminolevulinic acid hydrochloride

delta-Aminolevulinic acid hydrochloride

C5H10ClNO3 (167.0349)


   

thioguanine

6-Thioguanine

C5H5N5S (167.0266)


L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01B - Antimetabolites > L01BB - Purine analogues C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2254 - Amidophosphoribosyltransferase Inhibitor D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents 6-Thioguanine (Thioguanine; 2-Amino-6-purinethiol) is an anti-leukemia and immunosuppressant agent, acts as an inhibitor of SARS and MERS coronavirus papain-like proteases (PLpros) and also potently inhibits USP2 activity, with IC50s of 25 μM and 40 μM for Plpros and recombinant human USP2, respectively.

   

8-Hydroxy-guanine

8-Hydroxy-guanine

C5H5N5O2 (167.0443)


   
   

8-Oxoguanine

2-Amino-1H-purine-6,8-dione

C5H5N5O2 (167.0443)


   

2,8-Dihydroxyadenine

2,8-Dihydroxyadenine

C5H5N5O2 (167.0443)


A member of the class of 6-aminopurines that is adenine bearing two hydroxy substituents at positions 2 and 8. It is a highly insoluble metabolite of adenine that causes radiolucent urolithiasis. It is produced by individuals who suffer from adenine phosphoribosyltransferase (APRT) deficiency, a rare autosomal recessive error of purine metabolism.

   

Demethylphosphinothricin

(2S)-2-Amino-4-(hydroxyphosphinyl)butanoic acid

C4H10NO4P (167.0347)


   

CHEMBRDG-BB 4005752

CHEMBRDG-BB 4005752

C8H9NOS (167.0405)


   

(R)-2-Morpholinecarboxylic acid HCl

(R)-2-Morpholinecarboxylic acid HCl

C5H10ClNO3 (167.0349)


   

6-nitropyridine-2-carboxamide

6-nitropyridine-2-carboxamide

C6H5N3O3 (167.0331)


   
   

3-Methoxybenzenecarbothioamide

3-Methoxybenzenecarbothioamide

C8H9NOS (167.0405)


   

2-Morpholinecarboxylic acid hydrochloride (1:1)

2-Morpholinecarboxylic acid hydrochloride (1:1)

C5H10ClNO3 (167.0349)


   

(4R)-4-Hydroxy-L-proline hydrochloride (1:1)

(4R)-4-Hydroxy-L-proline hydrochloride (1:1)

C5H10ClNO3 (167.0349)


   

3-Carbamoyl-2-pyrazinecarboxylic acid

3-Carbamoyl-2-pyrazinecarboxylic acid

C6H5N3O3 (167.0331)


   

3-Morpholinecarboxylic acid hydrochloride (1:1)

3-Morpholinecarboxylic acid hydrochloride (1:1)

C5H10ClNO3 (167.0349)


   

(5-Fluorofuro[2,3-b]pyridin-2-yl)methanol

(5-Fluorofuro[2,3-b]pyridin-2-yl)methanol

C8H6FNO2 (167.0383)


   

cis-4-Hydroxy-L-proline hydrochloride

cis-4-Hydroxy-L-proline hydrochloride

C5H10ClNO3 (167.0349)


   

1-bromohexane-6,6,6-d3

1-bromohexane-6,6,6-d3

C6H10BrD3 (167.0389)


   

5-Carboxypyridine-3-boronic Acid

5-Carboxypyridine-3-boronic Acid

C6H6BNO4 (167.039)


   

trans-4-fluoro-beta-nitrostyrene

trans-4-fluoro-beta-nitrostyrene

C8H6FNO2 (167.0383)


   

Butanedioate, 2,3-dihydroxy-, ammonium salt (1:1)

Butanedioate, 2,3-dihydroxy-, ammonium salt (1:1)

C4H9NO6 (167.043)


   

p-Fluoro-β-nitrostyrene

p-Fluoro-β-nitrostyrene

C8H6FNO2 (167.0383)


   

1-Fluoro-2-(2-nitrovinyl)benzene

1-Fluoro-2-(2-nitrovinyl)benzene

C8H6FNO2 (167.0383)


   

1-Fluoro-3-(2-nitrovinyl)benzene

1-Fluoro-3-(2-nitrovinyl)benzene

C8H6FNO2 (167.0383)


   

6-Amino-1,3-dihydro-2H-purine-2-thione

2H-Purine-2-thione, 6-amino-1,3-dihydro-

C5H5N5S (167.0266)


   

6-Fluoro-2H-1,4-benzoxazin-3(4H)-one

6-Fluoro-2H-1,4-benzoxazin-3(4H)-one

C8H6FNO2 (167.0383)


   

4-nitropyridine-2-carboxamide

4-nitropyridine-2-carboxamide

C6H5N3O3 (167.0331)


   

thiazolo[4,5-d]pyriMidine-2,7-diaMine

thiazolo[4,5-d]pyriMidine-2,7-diaMine

C5H5N5S (167.0266)


   

3-Nitrophenylboronic acid

3-Nitrophenylboronic acid

C6H6BNO4 (167.039)


   

2-Mercapto-N-methylbenzamide

2-Mercapto-N-methylbenzamide

C8H9NOS (167.0405)


   

3-nitropyridine-2-carboxamide

3-nitropyridine-2-carboxamide

C6H5N3O3 (167.0331)


   

2-Methyl-5,6-dihydrobenzo[d]thiazol-7(4H)-one

2-Methyl-5,6-dihydrobenzo[d]thiazol-7(4H)-one

C8H9NOS (167.0405)


   

N,N,N-Trimethylethanaminium bromide

N,N,N-Trimethylethanaminium bromide

C5H14BrN (167.031)


   

Aminolevulinic acid hydrochloride

5-Aminolevulinic acid hydrochloride

C5H10ClNO3 (167.0349)


D011838 - Radiation-Sensitizing Agents > D017319 - Photosensitizing Agents C1420 - Photosensitizing Agent D003879 - Dermatologic Agents 5-Aminolevulinic acid hydrochloride (5-ALA hydrochloride) is an intermediate in heme biosynthesis in the body and the universal precursor of tetrapyrroles.

   

Creatine hydrochloride

Creatine hydrochloride

C4H10ClN3O2 (167.0462)


   

5-Nitropyridine-2-carboxamide

5-Nitropyridine-2-carboxamide

C6H5N3O3 (167.0331)


   

7-Fluoro-2H-benzo[b][1,4]oxazin-3(4H)-one

7-Fluoro-2H-benzo[b][1,4]oxazin-3(4H)-one

C8H6FNO2 (167.0383)


   

(4-METHYL-4H-THIENO[3,2-B]PYRROL-5-YL)METHANOL

(4-METHYL-4H-THIENO[3,2-B]PYRROL-5-YL)METHANOL

C8H9NOS (167.0405)


   

3-aminooxolane-3-carboxylic acid,hydrochloride

3-aminooxolane-3-carboxylic acid,hydrochloride

C5H10ClNO3 (167.0349)


   

4-Fluoro-3-formylbenzamide

4-Fluoro-3-formylbenzamide

C8H6FNO2 (167.0383)


   

3-nitropyridine-4-carboxamide

3-nitropyridine-4-carboxamide

C6H5N3O3 (167.0331)


   

4-Methoxybenzenecarbothioamide

4-Methoxybenzenecarbothioamide

C8H9NOS (167.0405)


   

Ethanethioamide, 2-phenoxy-

Ethanethioamide, 2-phenoxy-

C8H9NOS (167.0405)


   

2-methoxybenzenecarbothioamide

2-methoxybenzenecarbothioamide

C8H9NOS (167.0405)


   

2-fluoro-4-isocyanato-1-methoxybenzene(SALTDATA: FREE)

2-fluoro-4-isocyanato-1-methoxybenzene(SALTDATA: FREE)

C8H6FNO2 (167.0383)


   

(2-Nitrophenyl)boronic acid

(2-Nitrophenyl)boronic acid

C6H6BNO4 (167.039)


   

4-Amino-6-fluoro-3H-isobenzofuran-1-one

4-Amino-6-fluoro-3H-isobenzofuran-1-one

C8H6FNO2 (167.0383)


   

5-amino-6,7-dihydro-5H-1-benzothiophen-4-one

5-amino-6,7-dihydro-5H-1-benzothiophen-4-one

C8H9NOS (167.0405)


   

Methyl2-amino-3-oxobutanoateHclsalt

Methyl2-amino-3-oxobutanoateHclsalt

C5H10ClNO3 (167.0349)


   

(4-Nitrophenyl)boronic acid

(4-Nitrophenyl)boronic acid

C6H6BNO4 (167.039)


   

(4R)-4-Hydroxy-D-proline hydrochloride (1:1)

(4R)-4-Hydroxy-D-proline hydrochloride (1:1)

C5H10ClNO3 (167.0349)


   

H-Gly-Gly-NH2 · HCl

H-Gly-Gly-NH2 · HCl

C4H10ClN3O2 (167.0462)


   

6,7-Dihydrobenzo[b]thiophen-4(5H)-oneoxime

6,7-Dihydrobenzo[b]thiophen-4(5H)-oneoxime

C8H9NOS (167.0405)


   

1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazol-5-ol

1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazol-5-ol

C4H4F3N3O (167.0306)


   

4,5,6,7-tetrahydrothieno[3,2-c]pyridine-2-carbaldehyde

4,5,6,7-tetrahydrothieno[3,2-c]pyridine-2-carbaldehyde

C8H9NOS (167.0405)


   

5-(Dihydroxyboryl)-2-pyridinecarboxylic acid

5-(Dihydroxyboryl)-2-pyridinecarboxylic acid

C6H6BNO4 (167.039)


   

4-acetamidothiophenol

4-acetamidothiophenol

C8H9NOS (167.0405)


   

2-Pyrrolidinone, 4-(2-Thienyl)

2-Pyrrolidinone, 4-(2-Thienyl)

C8H9NOS (167.0405)


   

Acetamide,2-mercapto-N-phenyl-

Acetamide,2-mercapto-N-phenyl-

C8H9NOS (167.0405)


   

4-amino-6-mercaptopyrazolo[3,4-d]pyrimidine

4-amino-6-mercaptopyrazolo[3,4-d]pyrimidine

C5H5N5S (167.0266)


   

tans-4-Hydroxy-D-proline hydrochloride

tans-4-Hydroxy-D-proline hydrochloride

C5H10ClNO3 (167.0349)


   

4-Methyl-3,4-dihydro-[1,2,3]triazolo[4,5-d]pyrimidine-5,7-dione

4-Methyl-3,4-dihydro-[1,2,3]triazolo[4,5-d]pyrimidine-5,7-dione

C5H5N5O2 (167.0443)


   

Vanillate

Vanillate

C8H7O4- (167.0344)


A methoxybenzoate that is the conjugate base of vanillic acid.

   

(3R,4R,5S,6R)-6-Fluoro-3,4,5-trihydroxytetrahydro-2H-pyran-2-olate

(3R,4R,5S,6R)-6-Fluoro-3,4,5-trihydroxytetrahydro-2H-pyran-2-olate

C5H8FO5- (167.0356)


   

(3,4-Dihydroxyphenyl)acetate

(3,4-Dihydroxyphenyl)acetate

C8H7O4- (167.0344)


A dihydroxy monocarboxylic acid anion that is the conjugate base of (3,4-dihydroxyphenyl)acetic acid, arising from deprotonation of the carboxy group. COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Homogentisate

Homogentisate

C8H7O4- (167.0344)


A dihydroxy monocarboxylic acid anion that is the conjugate base of (2,6-dihydroxyphenyl)acetic (homogentisic) acid, arising from deprotonation of the carboxy group.

   

4-Hydroxymandelate

4-Hydroxymandelate

C8H7O4- (167.0344)


A 2-hydroxycarboxylate that is obtained by removal of a proton from the carboxylic acid group of 4-hydroxymandelic acid.

   

2-{[Amino(iminio)methyl]amino}ethanesulfonate

2-{[Amino(iminio)methyl]amino}ethanesulfonate

C3H9N3O3S (167.0365)


   

(R)-4-Hydroxymandelate

(R)-4-Hydroxymandelate

C8H7O4- (167.0344)


   

(S)-4-Hydroxymandelate

(S)-4-Hydroxymandelate

C8H7O4- (167.0344)


   

(Sulfuric acid pentyl)anion

(Sulfuric acid pentyl)anion

C5H11O4S- (167.0378)


   

2,4-Dihydroxy-6-methylbenzoate

2,4-Dihydroxy-6-methylbenzoate

C8H7O4- (167.0344)


   

4-Hydroxy-3-(hydroxymethyl)-benzoate

4-Hydroxy-3-(hydroxymethyl)-benzoate

C8H7O4- (167.0344)


   

4-Methylgentisate

4-Methylgentisate

C8H7O4- (167.0344)


   

3-Methylgentisate

3-Methylgentisate

C8H7O4- (167.0344)


   

3-Hydroxymandelate

3-Hydroxymandelate

C8H7O4- (167.0344)


   

3-Methoxysalicylate

3-Methoxysalicylate

C8H7O4- (167.0344)


   

2,3-Dihydroxy-4-toluenecarboxylate

2,3-Dihydroxy-4-toluenecarboxylate

C8H7O4- (167.0344)


   

[(S)-1-acetamidoethyl]phosphonic acid

[(S)-1-acetamidoethyl]phosphonic acid

C4H10NO4P (167.0347)


   

2-Hydroxy-5-(hydroxymethyl)benzoate

2-Hydroxy-5-(hydroxymethyl)benzoate

C8H7O4- (167.0344)


   

[(1R)-1-acetamidoethyl]phosphonic acid

[(1R)-1-acetamidoethyl]phosphonic acid

C4H10NO4P (167.0347)


   
   

3-Hydroxy-4-methoxybenzoate

3-Hydroxy-4-methoxybenzoate

C8H7O4- (167.0344)


A monohydroxybenzoate that is the conjugate base of 3-hydroxy-4-methoxybenzoic acid, arising from deprotonation of the carboxy group.

   

2-Hydroxy-4-methoxybenzoate

2-Hydroxy-4-methoxybenzoate

C8H7O4- (167.0344)


   

3,5-Dihydroxyphenylacetate

3,5-Dihydroxyphenylacetate

C8H7O4- (167.0344)


   

(2E,4Z)-2-Hydroxy-6-oxoocta-2,4,7-trienoate

(2E,4Z)-2-Hydroxy-6-oxoocta-2,4,7-trienoate

C8H7O4- (167.0344)


   

(2,6-Dihydroxyphenyl)acetate

(2,6-Dihydroxyphenyl)acetate

C8H7O4- (167.0344)


   

Taurocyamine

Guanidinoethyl sulfonate

C3H9N3O3S (167.0365)


   

phenylthioacetohydroximic acid

phenylthioacetohydroximic acid

C8H9NOS (167.0405)


   

(3,5-dihydroxyphenyl)acetate

(3,5-dihydroxyphenyl)acetate

C8H7O4 (167.0344)


A dihydroxy monocarboxylic acid anion that is the conjugate base of (3,5-dihydroxyphenyl)acetic acid, arising from deprotonation of the carboxy group; major microspecies at pH 7.3.

   

2,8-dioxoadenine

2,8-dioxoadenine

C5H5N5O2 (167.0443)


An oxopurine that is adenine bearing two oxo substituents at positions 2 and 8.

   

o-orsellinate

o-orsellinate

C8H7O4 (167.0344)


A dihydroxybenzoate that is the conjugate base of o-orsellinic acid.

   

Hydroxyguanine

Hydroxyguanine

C5H5N5O2 (167.0443)


   

tioguanine

tioguanine

C5H5N5S (167.0266)


   

2-imino-3h-purine-6,7-diol

2-imino-3h-purine-6,7-diol

C5H5N5O2 (167.0443)


   

4-amino-1h-pyrazolo[3,4-d]pyrimidine-3,6-diol

4-amino-1h-pyrazolo[3,4-d]pyrimidine-3,6-diol

C5H5N5O2 (167.0443)


   

n-(2-phosphonoethyl)ethanimidic acid

n-(2-phosphonoethyl)ethanimidic acid

C4H10NO4P (167.0347)